The JUPITER Trial: Responding to the Critics

      In January 2003, the Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) investigators began to enroll 17,802 men and women with no evidence of cardiovascular disease and normal to low levels of low-density lipoprotein (LDL) cholesterol into a controversial trial testing whether subjects with enhanced inflammatory responses might benefit from aggressive statin therapy. At study entry, the mean LDL cholesterol level for enrolled participants was just above 100 mg/dl, nearly half had Framingham scores of ≤10%, and none were considered candidates for statin therapy under any current set of prevention guidelines. However, all trial participants had levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, putting them at substantial risk for future cardiovascular disease.
      To read this article in full you will need to make a payment

      References

        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
        N Engl J Med. 2008; 359: 2195-2207
        • Glynn R.J.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • MacFadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Ridker P.M.
        A randomized trial of rosuvastatin in the prevention of venous thromboembolism.
        N Engl J Med. 2009; 360: 1851-1861
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.
        • Genest J.
        • Gotto Jr, A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • Macfadyen J.G.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
        Lancet. 2009; 373: 1175-1182
        • Ridker P.M.
        • Genest J.
        • Boekholdt S.M.
        • Libby P.
        • Gotto A.M.
        • Nordestgaard B.G.
        • Mora S.
        • MacFadyen J.G.
        • Glynn R.J.
        • Kastelein J.J.P.
        • JUPITER Trial Study Group
        HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
        Lancet. 2010; 376: 333-339
        • Glynn R.J.
        • Koenig W.
        • Nordestgaard B.M.
        • Shepherd J.
        • Ridker P.M.
        Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
        Ann Intern Med. 2010; 152: 488-496
        • Everett B.M.
        • Glynn R.J.
        • MacFadyen J.G.
        • Ridker P.M.
        rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
        Circulation. 2010; 121: 143-150
        • Mora S.
        • Glynn R.J.
        • Hsia J.
        • MacFadyen J.G.
        • Genest J.
        • Ridker P.M.
        Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia.
        Circulation. 2010; 121: 1069-1077
        • Ridker P.M.
        • MacFadyen J.
        • Cressman M.
        • Glynn R.J.
        Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein.
        J Am Coll Cardiol. 2010; 55: 1266-1273
        • Ridker P.M.
        • MacFadyen J.
        • Libby P.
        • Glynn R.J.
        Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
        Am J Cardiol. 2010; 106: 204-209
        • Ridker P.M.
        • MacFadyen J.G.
        • Fonseca F.A.
        • Genest J.
        • Gotto A.M.
        • Kastelein J.J.
        • Koenig W.
        • Libby P.
        • Lorenzatti A.J.
        • Nordestgaard B.G.
        • Shepherd J.
        • Willerson J.T.
        • Glynn R.J.
        Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).
        Circ Cardiovasc Qual Outcomes. 2009; 2: 616-623
      1. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiology. In press.

        • Ohsfeldt R.L.
        • Gandhi S.K.
        • Smolen L.J.
        • Jensen M.M.
        • Fox K.M.
        • Gold A.
        • Hsia J.
        Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
        J Med Econ. 2010; 13: 428-437
        • Genest J.
        • McPherson R.
        • Frohlich J.
        • Anderson T.
        • Campbell N.
        • Carpentier A.
        • Couture P.
        • Dufour R.
        • Fodor G.
        • Francis G.A.
        • Grover S.
        • Gupta M.
        • Hegele R.A.
        • Lau D.C.
        • Leiter L.
        • Lewis G.F.
        • Lonn E.
        • Mancini G.B.
        • Ng D.
        • Pearson G.J.
        • Sniderman A.
        • Stone J.A.
        • Ur E.
        2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations.
        Can J Cardiol. 2009; 25: 567-579
        • de Lorgeril M.
        • Salen P.
        • Abramson J.
        • Dodin S.
        • Hamazaki T.
        • Kostucki W.
        • Okuyama H.
        • Pavy B.
        • Rabaeus M.
        Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy.
        Arch Intern Med. 2010; 170: 1032-1036
        • Kaul S.
        • Morrissey R.P.
        • Diamond G.A.
        By Jove! What is a clinician to make of JUPITER?.
        Arch Intern Med. 2010; 170: 1073-1077
        • Green L.A.
        Cholesterol-lowering therapy for primary prevention.
        Arch Intern Med. 2010; 170: 1007-1008
        • The Cholesterol Treatment Trialists' Collaborators
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Ridker P.M.
        • Rifai N.
        • Clearfield M.
        • Downs J.R.
        • Weis S.E.
        • Miles J.S.
        • Gotto Jr, A.M.
        Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
        N Engl J Med. 2001; 344: 1959-1965
        • McMurray J.J.V.
        • Kjekshus J.
        • Gullestad L.
        • Dunselman P.
        • Hjalmarson A.
        • Wedel H.
        • et al.
        • CORONA Study Group
        Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
        Circulation. 2009; 120: 2188-2196
        • Yang E.Y.
        • Nambi V.
        • Tang Z.
        • Virani S.S.
        • Boerwinkle E.
        • Hoogeveen R.C.
        • Astor B.C.
        • Mosley T.H.
        • Coresh J.
        • Chambless L.
        • Ballantyne C.M.
        Clinical Implications of JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk in Communities) study.
        J Am Coll Cardiol. 2009; 54;: 2388-2395
        • The Emerging Risk Factors Collaboration
        C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
        Lancet. 2010; 375: 132-140
        • Hughes M.D.
        • Pocock S.J.
        Stopping rules and estimation problems in clinical trials.
        Stat Med. 1988; 7: 1231-1242
        • Pocock S.J.
        • Hughes M.D.
        Estimation issues in clinical trials and overviews.
        Stat Med. 1990; 9: 657-671
        • Montori V.M.
        • Devereaux P.J.
        • Adhikari N.K.J.
        • Burns K.E.A.
        • Eggert C.H.
        • Briel M.
        • et al.
        Randomized trials stopped early for benefit: a systematic review.
        JAMA. 2005; 294: 2203-2209
        • Friedlin B.
        • Korn E.
        Stopping clinical trials early for benefit: impact on estimation.
        Clin Trials. 2009; 6: 119-125
        • Korn E.L.
        • Friedlin B.
        • Mooney M.
        Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Experience from 1990 to 2005.
        J Clin Oncol. 2009; 27: 1712-1721
        • Sargent D.
        Early stopping for benefit in National Cancer Institute-sponsored randomized phase III trials: the system is working.
        J Clin Oncol. 2009; : 1543-1544
        • US Food and Drug Administration, Center for Drug Evaluation and Research
        (15 December 2008, Advisory Committee meeting for rosuvastatin (Crestor™)) (Accessed on August 28, 2010)
        • de Lorgeril M.
        • Renaud S.
        • Mamelle N.
        • Salen P.
        • Martin J.L.
        • Monjaud I.
        • Guidollet J.
        • Toubul P.
        • Delaye J.
        Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease.
        Lancet. 1994; 343: 1454-1459
        • Ridker P.M.
        • Glynn R.J.
        Rosuvastatin in patients with elevated C-reactive protein.
        N Engl J Med. 2009; 360: 1041-1042
        • Ray K.K.
        • Seshasai S.R.K.
        • Erqou S.
        • Sever P.
        • Jukema J.W.
        • Ford I.
        • Sattar N.
        Statins and all-cause mortality in high-risk primary prevention.
        Arch Intern Med. 2010; 170: 1024-1031
        • Brugts J.J.
        • Yetgin T.
        • Hoeks S.E.
        • Gotto A.M.
        • Shepherd J.
        • Westendorp R.G.J.
        • de Craen A.J.M.
        • Knopp R.H.
        • Nakamura H.
        • Ridker P.
        • van Domburg R.
        • Deckers J.W.
        The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials.
        BMJ. 2009; 338: b2376
        • Ridker P.M.
        • Torres J.
        Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000–2005.
        JAMA. 2006; 295: 2270-2274
        • Rajpathak S.N.
        • Kumbhani D.J.
        • Crandall J.
        • Barzilai N.
        • Alderman M.
        • Ridker P.M.
        Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
        Diabetes Care. 2009; 32: 1924-1929
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • Welsh P.
        • Buckley B.M.
        • de Craen A.J.M.
        • Seshasai S.R.K.
        • McMurray J.J.
        • Freeman D.J.
        • Jukema J.W.
        • Macfarlane P.W.
        • Packard C.J.
        • Stott D.J.
        • Westendorp R.G.
        • Shepherd J.
        • Davis B.R.
        • Pressel S.L.
        • Marchioli R.
        • Maggioni A.P.
        • Tavazzi L.
        • Tognoni G.
        • Kjekshus J.
        • Pedersen T.R.
        • Cook T.J.
        • Gotto A.M.
        • Clearfield M.B.
        • Downs J.R.
        • Nakamura H.
        • Ohashi Y.
        • Mizuno K.
        • Ray K.K.
        • Ford I.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742